Introduction
Aberrant DNA methylation has been established as one of the major mechanisms by which tumor suppressor genes are silenced in cancer (Baylin and Ohm, 2006) . Several genome-wide methylation assays have identified a large number of abnormal gene methylation in various malignancies (Kim et al., 2006; Meissner and Jaenisch, 2006; Shames et al., 2006; Jacinto et al., 2007; Bennett et al., 2008) . A genome-wide transcriptome-based approach that can identify novel genes silenced by methylation in cancer has been developed (Schuebel et al., 2007) . This approach relies on the differential response of densely methylated promoters to the demethylating agent 5-aza-2 0 -deoxycytidine (DAC) as compared with the histone deacetylase inhibitor trichostatin A (TSA). Using this approach we interrogated six lung tumor-derived cell lines and identified the CXC subfamily of chemokines as potential candidates for epigenetic silencing.
Chemokines are a superfamily of small chemotactic cytokines that direct the migration of leukocytes (Moser and Loetscher, 2001) . In addition, they regulate cellular processes such as proliferation, migration, angiogenesis and tumor-related immunity (Muller et al., 2001; Shellenberger et al., 2004; Strieter et al., 2004; Shurin et al., 2005) . Chemokines are classified into four subfamilies: C, CC, CXC and CX3C chemokines on the basis of the location of conserved cysteine residues . The CXC subfamily in humans consists of 16 members (CXCL1-14, 16 and 17) that are important regulators of tumor angiogenesis, immunity and tissue-specific cancer metastasis (Hromas et al., 1999; Strieter et al., 2004; Darash-Yahana et al., 2009; Mu et al., 2009; Yuvaraj et al., 2009) . CXC chemokines share four cysteine residues in a highly conserved location that determine the three-dimensional structures of these heparin-binding proteins. A glutamate-leucinearginine (ELR) motif near the N-terminus of the molecule determines the property of a specific chemokine. The ELR-positive chemokines, including CXCL1-3, 5-8, are proangiogenic, whereas members lacking the ELR motif, such as CXCL4, 9-11, are interferon inducible and are potential inhibitors of angiogenesis .
CXCL14, also known as BRAK, is an ELRnegative chemokine abundantly expressed in most normal tissues, including lungs (Kurth et al., 2001; Schwarze et al., 2005; Shurin et al., 2005; Ozawa et al., 2006; Parsanejad et al., 2008) . In contrast, the majority of established epithelial cancer cell lines and many primary carcinomas do not express CXCL14, suggesting a tumor suppressor function (Shellenberger et al., 2004; Shurin et al., 2005; Ozawa et al., 2006; McKinnon et al., 2008) . Interestingly, CXCL14 expression was suppressed by epidermal growth factor and restored by a epidermal growth factor receptor tyrosine kinase inhibitor (gefitinib) in the head and neck squamous-cell carcinoma cells (Ozawa et al., 2009 ). In addition, gefitinib-mediated re-expression of CXCL14 is strongly associated with the anti-tumor efficacy of this drug in head and neck squamous-cell carcinoma cell xenografts (Ozawa et al., 2009) .
The purpose of this study was to evaluate primary lung adenocarcinomas from current, former and never smokers for promoter hypermethylation of the CXC subfamily of chemokines identified by a genome-wide transcriptome array. Cancer specificity was determined by comparing methylation in lung cancer cell lines to normal human bronchial epithelial cells (NHBECs) from bronchoscopy of cancer-free smokers and to normal peripheral blood mononuclear cells (PBMCs) of healthy donors. The potential use of aberrant methylation of these genes as biomarkers for early lung cancer detection was assessed using sputum samples from early-stage lung cancer cases and from controls. Finally, in vitro and in vivo studies were also conducted to evaluate the functional consequences associated with silencing of CXCL14.
Results

DNA methylation regulates transcription of CXC chemokines in lung cancer
A genome-wide transcriptome array designed to discover novel aberrantly methylated genes identified 11 of the 16 known CXC genes 8, (10) (11) (12) 14 and 16) in human lung cancer cell lines ( Figure 1a and Table 1 ). Nine genes (CXCL1-6, 12, 14, and 16), including seven identified by the array, have promoter CpG islands (Table 1; Gardiner-Garden and Frommer, 1987) . The specificity of promoter methylation to tumor cells was validated by combined bisulfite restriction analysis (COBRA) using lung cancer cell lines, PBMCs from healthy donors and NHBECs obtained from the bronchoscopy of cancer-free smokers. Tumor-specific methylation (not detected in NHBECs) of CXCL5, CXCL6, CXCL12 and CXCL14 was found in 65, 65, 63 Figure 1 Transcription of the CXC chemokines in lung cancer is regulated by methylation. (a) Genes that are most likely regulated by promoter hypermethylation are expected in the top tier group (twofold or higher change with DAC treatment (y axis 4 1.4) and little or no change with TSA treatment (x axis ¼ À0.5 to 0.5)). Treatment of H23 cells with DAC led to an 18.2, 2.4 and 2.2-fold increase in expression of CXCL5, CXCL11 and CXCL14, respectively, on Agilent 44K expression array. In contrast, H23 cells treated with TSA showed little or no change in the expression of these genes suggesting that DNA methylation is the primary regulator of the transcription of these genes in H23. Primary lung adenocarcinomas from current, former and never smokers showed tumor specific and highly prevalent methylation in the promoter CpG island of CXCL5 (b), CXCL12 (c) and CXCL14 (d). and 59% of lung cancer cell lines, respectively. In contrast, CXCL4 was methylated in 82% of the lung cancer cell lines, 90% of NHBECs and 100% of PBMCs, and CXCL6 was methylated in 55% of PBMCs. Although, CXCL4 and CXCL6 were methylated in lung cancer cell lines, the frequent methylation of these genes in PBMCs negated their evaluation in primary adenocarcinomas. The promoter CpG islands of the remaining four genes (CXCL1, 2, 3 and 16) were unmethylated in all lung cancer cell lines (Table 1) .
Methylation of CXCL5, 12 and 14 is common in primary lung adenocarcinomas The methylation status of CXCL5, 12 and 14 promoters was evaluated in primary lung adenocarcinomas using methylation-specific PCR (MSP), and methylation was found in 80, 75 and 78% of the tumors, respectively (Figures 1b-d ). All three genes were methylated in 107 (61%) of the primary tumors, whereas only 7 (4%) showed unmethylated promoter in all three genes. Although the prevalence for methylation of CXCL14 is slightly higher in never smokers than in current and former smokers, the difference was not statistically significant ( Figure 1d ). Similarly, the prevalence for CXCL5 and CXCL12 methylation among the different smoking groups was similar (Figures 1b and c). There was no difference in prevalence for gene methylation by the tumor stage, and methylation of these chemokines alone or in combination was not prognostic for survival (not shown).
Methylation of CXCL5, 12 and 14 silences the gene expression
The effect of methylation on gene expression was compared between samples with and without methylation of CXCL5, 12 and 14 promoters using reverse trancriptase PCR (RT-PCR). Complete methylation of these genes (determined by a complete digestion of multiple CGCG sites by the BstUI restriction enzyme) strongly correlated with the loss of gene expression. In lung cancer cell lines with completely methylated CXCL5 (H1568, H1993 and Calu-6), CXCL12 (Calu-6 and SKLU-1) and CXCL14 (H23, Calu-6 and SKLU-1), transcription of these genes was absent (Figures 2a-c) . In contrast, all three genes were readily transcribed in samples with unmethylated promoters such as NHBECs and H2228.
DAC treatment restores expression of genes silenced by methylation
The causality of promoter hypermethylation and/or histone modification to gene silencing was evaluated using drugs to inhibit DNA methylation (DAC) and histone deacetylation (TSA). Lung cancer cell lines with or without methylation of CXCL5, 12 and 14 promoters were treated with vehicle (sham), TSA or DAC, and gene expression was evaluated by RT-PCR. DAC treatment restored the expression of CXCL5 (H1568, H1993 and Calu-6), CXCL12 (Calu-6 and SKLU-1) and CXCL14 (H23, Calu-6 and SKLU-1) to a level comparable to the cell lines without methylation . TSA was unable to restore expression of these genes in cell lines where dense methylation within the promoter CpG islands was detected by the COBRA assay. The only exceptions to this scenario were CXCL5 in H1993 and CXCL14 in Calu-6, where response to DAC and TSA was similar. Interestingly, CXCL14 was completely silenced in H2023 and H1568 where the promoter CpG island is unmethylated or weakly methylated, and expression was restored primarily by TSA suggesting that histone modification is the predominant cause of CXCL14 silencing in these cell lines (Figure 2c ). Array positive indicates the number of lung adenocarcinoma cell lines (out of six cell lines) that showed a twofold or higher increase in expression after DAC treatment.
Re-expression of CXCL14 induces tumor necrosis M Tessema et al (c) was silenced in untreated control (S) lung cancer cell lines with methylated promoter CpG islands and could be restored primarily with DAC (D) treatment. In some cell lines (CXCL5 in H1993, and CXCL14 in Calu-6), gene expression could also be restored by TSA (T) treatment. NHBECs and lung cancer cell lines, with unmethylated promoter CpG islands, readily expressed these chemokines and their expression was not affected by treatment with either drugs. CXCL14 expression in H2023 and H1568 cell lines was silenced in the absence of methylation and expression was primarily restored by TSA treatment. (d) Dense methylation that corresponds with gene silencing was found in the promoter CpG island of CXCL14. Modified DNA was amplified using primers that do not discriminate between methylated and unmethylated alleles (the same used for COBRA), cloned and five clones per sample were sequenced. The shaded area of each circle indicates the extent of methylation at that CpG and one clone represents one-fifth of the circle. CpGs 10-12 and 20-23 (placed in boxes) indicate the primer binding sites for the MSP assay and the CpGs recognized by BstU1 restriction enzyme used for COBRA are indicated by asterisks. Nearly all CpGs of samples that were unmethylated by COBRA and MSP assays (NHBECs 255 and 256, H1435 and primary lung adenocarcinoma sample #18) were free of methylation. Only 0-8% of the 260 CpGs (52 CpGs per clone and five clones per sample) were methylated in these samples. In contrast, 58-100% of the CpGs were methylated in samples that were strongly methylated by COBRA and MSP (H23, Calu-6 and primary tumor #54, #66 and #100). Primary adenocarcinoma #35 that was weakly methylated by the two assays was methylated for 33% of the CpGs.
Re-expression of CXCL14 induces tumor necrosis M Tessema et al
Because epigenetic regulation of CXCL14 is unknown, unlike CXCL5 and CXCL12 (Speetjens et al., 2008; Wendt et al., 2008) , studies on this cytokine were extended to map the distribution of methylation across the promoter CpG island. Out of 82 CpGs present within the promoter CpG island of CXCL14, 52 were analyzed using sodium bisulfite sequencing. Primary lung adenocarcinomas and lung cancer cell lines that were strongly positive for methylation in the MSP and COBRA (#54, #66, #100, H23 and Calu-6) were methylated for 58-100% of the 260 CpG islands evaluated (52 CpGs per clone and five clones per sample; Figure 2d ). In contrast, samples with no methylation (#18, H1435 and the NHBECs N255 and N256) or weak methylation (#35) in the MSP and COBRA assays were methylated in 0-8 and 33% of the CpGs, respectively (Figure 2d ).
Methylation of CXCL14 is a diagnostic marker for early-stage lung cancer Detection of aberrant gene methylation in sputum is emerging as a promising early biomarker for lung cancer (Belinsky et al., 2006) . Therefore, methylation of CXCL12 and CXCL14 was evaluated using sputum samples collected from asymptomatic stage I lung cancer cases (n ¼ 40) and cancer-free smokers (control, n ¼ 80) matched by age, gender, smoking status (current, former) and enrollment site. The low number of CpGs within CXCL5 promoter CpG island (Table 1) prohibited the development of a sensitive and specific nested MSP assay required for interrogating DNA recovered from sputum samples. CXCL14 was methylated in 55% of cases compared with 33.8% in controls, indicating a 2.9-fold increased risk (95% CI: 1.7, 7.3; P ¼ 0.026) for lung cancer. Similarly, CXCL12 was methylated in 50% cases compared with 37.5% in controls suggesting an elevated, albeit not significant, 1.7-fold increased risk for lung cancer (95% CI: 0.7, 3.3; P ¼ 0.24). As expected, the prevalence for methylation of these chemokines in sputum samples that contain cells from both deep lung parenchyma and airways reflecting field cancerization was greater than that seen in cytologically-normal bronchial epithelial cells obtained by bronchoscopy.
CXCL14 expression increases cell death
The effect of CXCL14 expression on cell survival and proliferation was evaluated using H23 and SKLU1 cells where this gene is completely silenced by methylation. Control GFP CXCL14-GFP *p<0.01 Figure 3 Transient re-expression of CXCL14 induces cell death. Cell survival was evaluated by flow cytometry using a GFP containing expression vector. The normal level of cell death, which occurs in 4-5% of H23 cells (a) was increased to 15-20% because of the exposure to transfection reagent alone (data not shown). GFP expression in the transfected cells increased cell death by 20-25%, which was only marginally greater than that seen with the transfection media (b). In contrast, expression of CXCL14-GFP led to a 40-45% cell death (c). This indicates that re-expression of CXCL14 in H23 cells where the endogenous expression is silenced by methylation increased cell death by 19.3 % compared with the GFP control (d).
Re-expression of CXCL14 induces tumor necrosis M Tessema et al expression of CXCL14-GFP also led to a 6% reduction in the number of actively cycling (G2-M phase) cells compared with the GFP control, the difference was not statistically significant (P ¼ 0.28; data not shown). In addition, migration of serum-starved H23 cells with or without stable CXCL14 expression was compared using cell migration chambers with 8 mm pores and H23 growth media containing 10% fetal bovine serum as a chemo-attractant. Stable expression of CXCL14 increased cell migration by 40% (Po0.01) compared with the parental cells (Supplementary Figure S2 ).
CXCL14 expression dramatically suppresses tumor growth in nude mice through induction of tumor necrosis
The candidate tumor suppressor function of CXCL14 was examined in vivo by comparing the tumorigenicity in nude mice of H23 cells with or without stable CXCL14 expression. Parental H23 cells with silenced CXCL14 and H23 clone (H23-CXCL14) stably expressing this chemokine (Figure 4a , inset) were subcutaneously injected into nude mice, and tumor growth was monitored for 10 weeks. Tumor growth was comparable between the two cell lines for the first 4 weeks. However, Figure 4 Stable re-expression of CXCL14 significantly reduced tumor growth and induced necrosis of H23 xenografts in nude mice. (a) Both the parental and CXCL14-expressing H23 cells formed detectable tumors within 2 weeks post-inoculation and showed comparable rates of tumor growth in the first 4 weeks. After week 4, tumors from the parental H23 kept growing whereas those from CXCL14-expressing cells barely increased in size. The asterisks at weeks 6, 9 and 10 indicate significant differences in tumor size. (b) The size difference between the tumors in the two groups was obvious under the skin when the mice were killed 10 weeks postinjection. (c) Similarly, the size and weight of the tumors harvested from the CXCL14-expressing cells were significantly smaller than tumors from the parental H23 cells. (d) Histological examination of hematoxylin and eosin stained slides revealed tumors from the CXCL14-expressing cells containing large necrotic foci that involved up to 90% of the tumor mass as compared with tumor necrosis in the range of 20-30% of the tumor mass from the parental H23 cells.
Re-expression of CXCL14 induces tumor necrosis M Tessema et al H23-CXCL14 tumors showed small additional increase in size whereas the parental line continued to grow (Figure 4a ). The mice in both groups were killed 10 weeks post-inoculation, the tumors were collected, and the tumor volume and weight were measured. Tumors derived from the H23-CXCL14 cells were significantly smaller in size and weight than tumors from the parental H23 cell line (Figures 4a-c) . Consistent with the flow cytometric cell death assay, hematoxylin and eosin stained tumor sections revealed large areas of necrosis encompassing 50-90% of the CXCL14-expressing cell tumor mass compared with 10-30% tumor necrosis in CXCL14-negative tumors (Figure 4d ).
CXCL14 re-expression modulates pathways leading to cell-cycle arrest and cell death Genome-wide transcription patterns of H23 cells with or without stable CXCL14 expression were compared to identify pathways that might be altered by CXCL14. As compared with the parental H23, the CXCL14-expressing clone showed 659 and 445 genes with over twofold increased and decreased expression, respectively (data not shown). Because functional studies suggest a role for CXCL14 in cell cycle and cell death, we focused our evaluation of the microarray data on genes regulating these two pathways. Consistent with the in vitro and in vivo studies, expression of 30 genes that directly or indirectly inhibit cell-cycle progression or promote apoptosis was increased in the CXCL14-expressing cells (Table 2) . Moreover, expression of 41 genes that promote DNA replication, cell-cycle progression and cytokinesis, or expression of genes with anti-apoptosis and/or oncogenic properties was significantly reduced in the CXCL14-expressing cells. Fold expression changes and gene function are detailed in Table 2 . Most notable, were the 4-7.6-fold increase in the expression of caspases and the 20-fold increase in the expression of TXNIP, an inducer of G1 cell cycle arrest. In contrast, expression of the cyclin family of genes (A2, A3, B1, D3 and E2) that promote cell-cycle progression was reduced by 45-70% (Table 2) .
Discussion
Chemokines regulate cell proliferation, apoptosis, angiogenesis, metastasis and tumor immunity, pathways that are critical in carcinogenesis (Hromas et al., 1999; Strieter et al., 2004; Darash-Yahana et al., 2009; Mu et al., 2009) . A genome-wide transcriptome array identified the CXCL5, CXCL12 and CXLC14 chemokines as common targets for silencing by promoter methylation in adenocarcinomas. Dense methylation that was reversible by treatment with a demethylating agent accounted for silencing of all three genes. Strong support for CXCL14 as a tumor suppressor gene was provided by its marked effect on the growth of tumor xenografts, induction of tumor necrosis and likely influence on many genes central to cell-cycle control and apoptosis. The commonality and diverse function of the multitude of genes silenced by methylation in lung tumors has generated intense interest by our group and others for assessing their potential as biomarkers through detection of methylated genes in sputum from asymptomatic lung cancer patients (Belinsky et al., 1998 (Belinsky et al., , 2006 Cirincione et al., 2006; Hsu et al., 2007) . CXCL14 methylation in sputum was associated with a 2.9-fold elevated risk for lung cancer, making it a potential marker for inclusion in our developing diagnostic gene panel (Belinsky et al., 2006) . The genome-wide transcriptome array developed to discover novel methylated genes in cancer, identified 11 of the 16 CXC chemokines as potential targets of DNA methylation in lung cancer. Five of the eight genes identified by the array that contained promoter CpG islands were methylated in lung cancer cell lines, a 62.5% accuracy for identifying genes regulated by methylation. However, two of the five methylated genes were also methylated in normal cells, (CXCL4 in NHBECs and PBMCs, and CXCL6 in PBMCs) indicating that gene regulation through methylation can be cell specific and related to the state of differentiation. This conclusion is supported by our previous study identifying four genes, within the lung cancer susceptibility locus 6q23-25, that were methylated in lymphocytes and two genes methylated in NHBECs (Tessema et al., 2008) . Recently, a genomewide screen for methylation also showed that approximately 10% of all promoters were methylated in differentiated B cells (Rauch et al., 2009) .
The expression of CXCL2, 3 and 16 that contain promoter CpG islands was significantly increased by DAC treatment; however, methylation of these genes was not seen in any lung cancer cell line. One explanation for this epigenetic regulation is re-expression of methylated genes, the proteins of which function as transcription factors to regulate expression of these chemokines. Although detailed studies have not been conducted to map transcription factor binding sites within these chemokines, our own studies on regulation of the PAX5 b gene support this premise. PAX5 b is commonly silenced in lung cancer through methylation and encodes for the transcription factor B cell-specific activating protein that, in turn, directly regulates CD19, a gene not containing a CpG island. A strong association was observed between PAX5 b methylation and loss of expression of CD19, and treatment with a demethylating agent restored expression of both genes (Palmisano et al., 2003) . Unlike lung cancer, CXCL16 is commonly silenced by methylation in kidney tumors (Morris et al., 2008) . In addition, RNA interferencemediated knock down of DNMT3a in melanoma cells resulted in CXCL9 and CXCL16 re-expression that was associated with suppression of tumor growth and metastasis, suggesting methylation-mediated regulation of these chemokines in other tumors (Deng et al., 2009 ).
Among the CXC chemokines with tumor-specific methylation in lung cancer, the role of CXCL12 in carcinogenesis is well established. Whereas CXCL12 is frequently methylated in various carcinomas, its cell surface receptor (CXCR4) is abundantly expressed in (Wendt et al., 2006 (Wendt et al., , 2008 Zhou et al., 2008; Yoshino et al., 2009 ). This limits the CXCL12-CXCR4 autocrine signaling and promotes directional migration of carcinoma cells toward organs/tissues with high CXCL12 expression. Lung is one of the organs expressing higher levels of CXCL12 and is a primary site for metastasis of carcinomas with low CXCL12 expression, such as breast and colorectal cancers (Muller et al., 2001) . Conversely, when CXCL12 is silenced in lung cancer, it may enhance the local invasion as well as metastasis to other organs with high CXCL12 expression, such as the adrenal glands, liver and bone marrow (Phillips et al., 2003) . Therefore, methylation-mediated silencing of CXCL12 in lung cancer could have a major role in deregulating the autocrine CXCL12-CXCR4 signaling pathway to promote tumor invasion and metastasis. Unlike CXCL12, the role of CXCL5 in cancer is unclear and likely varies in different malignancies. Small hairpin RNA knockdown of CXCL5 in colon cancer increased tumor growth and metastasis that is reversed by restoring CXCL5 expression suggesting a tumor suppressor function (Speetjens et al., 2008) . In contrast, expression of CXCL5 is increased in metastatic head and neck squamous-cell carcinoma and it promotes cell proliferation, whereas small hairpin RNA knockdown of CXCL5 suppresses cell migration, proliferation and tumorigenicity in nude mice suggesting an oncogenic role (Miyazaki et al., 2006) . Although CXCL5 is clearly silenced through methylation in lung cancer, its elevated expression in NSCLC could be from stromal cells within the tumor (Arenberg et al., 1998) .
CXCL14 is a potent angiostatic chemokine that blocks CXCL8-(interleukin 8), vascular endothelial growth factor-and basic fibroblast growth factormediated angiogenesis (Shellenberger et al., 2004) . It is also a chemo-attractant mediating infiltration of dendritic cells into tumors, which is critical for tumor immunity (Shurin et al., 2005) . As shown in this study, re-expression of CXCL14 enhances the cell death in vitro and induces marked necrosis in lung tumor xenografts, due in part through increased expression of multiple apoptosis effector proteins, including the caspases. Moreover, re-expression of CXCL14 has a profound effect on the genome altering the expression of more than 1000 genes. Taken together, these results suggest that CXCL14 expression is central for various antitumor mechanisms and its silencing could be critical for carcinogenesis.
Aberrant methylation may ultimately serve two vital roles in cancer: as biomarkers for detection and prognosis, and targets for epigenetic therapy (Belinsky et al., 2003 (Belinsky et al., , 2006 Gore et al., 2006; Yang et al., 2006) . CXCL14 may participate in both arenas. We are developing a gene panel, methylation of which in the sputum could identify people at high risk for cancer incidence. Previously, 6 of 14 genes evaluated in a lung cancer case-control study were associated with over 50% increase in lung cancer risk. Importantly, concomitant methylation of three or more of these six genes increased the risk by 6.5-fold with a sensitivity and specificity of 64% for classifying lung cancer cases. Although this sensitivity and specificity is not high enough for prospective population-based screening, Rather than targeting single pathway alterations in cancer, epigenetic therapy may circumvent the problem of tumor heterogeneity by inducing the re-expression of multiple tumor suppressor genes; several may be essential for abrogating cancer-cell survival and proliferation. Demethylating agents used at doses far below their maximum tolerated dose have proven to be a potent therapy for a precursor state to acute myelogenous leukemia and myelodyplasia, and are now approved by the Food and Drug Administration for treatment of these cancers (Yang et al., 2006) . Clinical trials with demethylating agents combined with histone deacetylase inhibitors also are showing promising responses in the treatment of myeloid malignancies (Gore et al., 2006) . The extension of this targeted approach to solid tumors, such as those in the lung, may also hold promise as a therapy. Our recent work, in which combined treatment with DAC and sodium phenylbutyrate reduced the number of developing lung tumors in a murine model by more than 50% support this supposition and phase II trials in lung cancer are under way (Belinsky et al., 2003) . The effective awakening of silenced genes, such as CXCL14, that can affect the activity of many critical pathways could profoundly impact the growth and survival of tumor cells setting the stage for using epigenetic therapy in the management of lung cancer in some patients.
Materials and methods
Samples
Frozen lung adenocarcinomas from current (n ¼ 37), former (n ¼ 59) and never (n ¼ 75) smokers were obtained from tumor banks at Johns Hopkins (Baltimore, MD, USA) and the Mayo Clinic (Rochester, MN, USA). Demographic variables including age, gender and stage of lung cancer, and selection criteria for suitable adenocarcinomas has been described previously (Tessema et al., 2008) . NHBECs isolated from bronchoscopy of cancer-free smokers (n ¼ 20) and PBMCs from healthy donors (n ¼ 20) were used as controls. A total of 17 lung cancer-derived cell lines (H23, H358, H1435, H1568, H1993, H2023, H2085, H2228, H2009, Calu-3, Calu-6, SKLU-1, SKMES1, H1299, H1975, HCC827 and HCC4006) were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). Sputum samples collected from stage I NSCLC cases before surgery (n ¼ 40) and from cancer-free smokers (n ¼ 80), and were matched based on age (±5 years), gender, smoking status (current, former) and location of hospital as described (Chin et al., 2008) .
Treatment and genome-wide transcriptome array Three lung adenocarcinoma cell lines (H23, H1568 and H1993) from smokers and three (H2023, H2085 and H2228) from never smokers were used for the transcriptome array as described (Tessema et al., 2008) . Briefly, cells at log phase of growth were treated as follows: control (culture medium), TSA (culture medium containing 300 nM of TSA (Sigma, St Louis, MO, USA; stock solution 5 mM in ethanol)) for 18 h), or DAC (500 nM; Sigma; stock solution 10 mM in phosphate-buffered saline (PBS)) for 96 h with fresh medium containing the drug changed every 24 h). Cells were harvested in TRI reagent (Sigma-Aldrich, Steinheim, Germany) and genome-wide transcriptome array analysis was conducted using the Agilent 44 K expression array as described (Tessema et al., 2008) .
DNA methylation analysis
DNA was extracted and modified as described (Tessema et al., 2009 ) and 40 ng of modified DNA was used per PCR. Methylation in NHBECs, PBMCs, primary lung tumors and cancer cell lines was studied using COBRA and MSP as described (Tessema et al., 2009) . Methylation of DNA isolated from sputum was assessed using a nested MSP assay developed as described (Belinsky et al., 2006) . Primer sequences and PCR conditions are described in Supplementary Tables S1 and S2. Bisulfite sequencing of CXCL14 promoter CpG island was conducted using modified DNA and COBRA primers ( Supplementary Table S1 ) that do not discriminate between methylated and unmethylated DNA. PCR products were cloned into pCR II cloning vector (Invitrogen, Santa Clara, CA, USA) and five clones were sequenced per sample.
Gene expression analysis
Total RNA (3 mg) isolated from sham-(vehicle), TSA-and DAC-treated cells as described (Tessema et al., 2009 ) was reverse transcribed using the SuperScript first-strand synthesis system for RT-PCR (Invitrogen) according to the manufacturer's instructions. Transcription of CXCL5, 12 and 14 was evaluated using RT-PCR and electrophoresis in 3% agarose gels. To avoid PCR products from DNA, RNA was treated with DNase and PCR primers were located in exons separated by a large intron. For CXCL14 transcripts originating from plasmid vectors (no intron), RT-negative (RTÀ) PCR was performed in parallel using complementary DNA synthesized in the absence of Superscriptase-II. RT-PCR primers and amplification conditions are described in Supplementary Table S3 .
Cloning, transfection and establishment of stable CXCL14expressing clones Full-length CXCL14 transcript amplified by PCR using complementary DNA from NHBECs 255 CXCL14 F2/R2 primer pairs ( Supplementary Table S3 ) was directly ligated into pcDNA3.1/NT-GFP-TOPO vector (Invitrogen) for transient transfection and into pTARGET mammalian expression vector system (Promega, Madison, WI, USA) for stable expression and was cloned by TA cloning strategy. The sense orientation and sequences of the cloned CXCL14 complementary DNA was confirmed by DNA sequencing. H23 cells (1 Â 10 5 /well in six-well plate) were transfected with CXCL14-GFP or the GFP-expression vector (mock) using lipofectamine LTX (Invitrogen). Stable transformants were selected from CXCL14 and mock pTARGET vector-transfected H23 cells using 400 mg/ml Geneticin (geneticin liquid (G-418 sulfate), Invitrogen).
Cell death, cell cycle and cell migration assays H23 cells were plated at a density of 1 Â 10 5 /well in six-well plates and transfected 24 h later with mock (GFP) or CXCL14-GFP vectors. For cell death analysis, cells were harvested (48 h post-transfection) with trypsin, washed once with PBS, stained in the dark with 10 mg/ml propidium iodide (PI; Sigma-Aldrich) at 37 1C for 1 h, washed and resuspended in 1 ml PBS, and the PI and GFP fluorescence were evaluated using flow cytometry (FACScalibur Flow Cytometer, Becton Dickinson). The proportion of PI-and/or GFP-positive cells was calculated from 10 000 events. For cell-cycle analysis, cells were plated, transfected, harvested and washed as described above, and resuspended in 500 ml ice-cold PBS, fixed by adding 500 ml of ice-cold 2% buffered paraformaldehyde and incubated at 4 1C for 30 min. The cells were then washed, permeablized with 1 ml ethanol at 4 1C overnight, stained with 1 ml PI solution containing 40 mg/ml PI, 100 mg/ml RNase in PBS at 37 1C for 1 h in the dark, washed, resuspended in PBS and cells were analyzed with flow cytometry as described above. For cell migration, H23 cells with or without stable CXCL14 expression were serum-starved for 48 h and cell migration was measured using CytoSelect 24-well cell migration assay (8 mm, Colorimetric Format; Cell Biolabs, San Diego, CA, USA) and 10% serum containing growth medium as a chemo-attractant for 24 h according to the protocol.
In vivo tumor growth Matrigel basement membrane matrix (BD Biosciences, San Jose, CA, USA) was mixed 1:1 with H23-CXCL14 clone stably expressing CXCL14 and the parental H23 cell line, and was subcutaneously injected (5 Â 10 6 /site) into both sides of the dorso-lateral region of four female athymic nude mice (Athymic NCr-nu/nu, Frederick, MD, USA) per group. Tumor size was quantified once a week from second to tenth week post-injection and tumor volume was calculated as: (a Â b 2 )/2, where a and b represent the longer and shorter dimensions, respectively. On the tenth week, all mice were killed, and tumors were collected and weighed. Tumors were formalin-fixed, paraffin-embedded, sectioned and stained with hematoxylin and eosin.
